Daily non-political popular news in brief.

Long-term etanercept treatment reduces psoriasis severity without increased adverse events

Extended exposure to the psoriasis medication etanercept does not appear to cause more infections or adverse events than placebo, and improvements in several measures of disease severity were observed for up to 96 weeks of therapy, according to a study in the June issue of Archives of Dermatology, one of the JAMA/Archives journals.

Read more »

Keywords: long-term, etanercept, treatment, psoriasis, severity, increased, adverse, events, long, term, psoriasi, event

« Previous | Next »

Similar news on "Long-term etanercept treatment reduces psoriasis severity without increased adverse events":

1. Children's ability to describe past event develops over time
   07-20-2007 · EurekAlert!
   A study analyzing forensic interviews with 250 4- to 10-year old children found many age-related differences in children’s recall of events experienced. Children’s mention of time, date, or sequence related to events increased as they grew older, with the most dramatic increases after age 10. Older children used short- and long-term scale patterns, while younger children referenced short-term time identifiers. These findings have important implications for using information from forensic interviews with children.
   Similar news · Read more »
   
2. Patients at risk of adverse events within 3 months after stopping certain ACS therapy
   02-05-2008 · EurekAlert!
   Patients who receive the anti-platelet medication clopidogrel following an acute coronary syndrome (such as heart attack) appear to be at greater risk of a heart attack or death in the first 90 days after stopping clopidogrel treatment, according to a study in the Feb. 6 issue of JAMA.
   Similar news · Read more »
   
3. Researchers Find Deadly Prescription Drug Effects Six Years Before FDA
   05-28-2007 · EurekAlert!
   Northwestern University's national SWAT team of doctor sleuths called RADAR (Research on Adverse Drug Events and Reports) identifies deadly prescription drug reactions six years before the FDA and drug companies. RADAR also provides more comprehensive reports with important medical insights as well as guidance for prevention, diagnosis and treatment.
   Similar news · Read more »
   
4. New analyses reinforce efficacy of Remicade in treatment of severe psoriasis
   02-02-2007 · EurekAlert!
   Findings from an integrated analysis of data from three pivotal, randomized, placebo-controlled trials showed that at week 10 more than three-quarters of patients with severe psoriasis receiving Remicade (infliximab) 3 mg/kg or 5 mg/kg achieved a 75 percent improvement in the chronic, inflammatory skin disease as measured by the Psoriasis Area Severity Index (PASI 75).
   Similar news · Read more »
   
5. Researchers find deadly prescription drug effects 6 years before FDA
   05-28-2007 · EurekAlert!
   Northwestern University's national SWAT team of doctor sleuths called RADAR (Research on Adverse Drug Events and Reports) identifies deadly prescription drug reactions six years before the FDA and drug companies. RADAR also provides more comprehensive reports with important medical insights as well as guidance for prevention, diagnosis and treatment.
   Similar news · Read more »
   
6. HORIZONS AMI trial data will help set guidelines
   10-24-2007 · EurekAlert!
   Late-breaking data presented at TCT 2007, the scientific symposium of the Cardiovascular Research Foundation, show that the use of the anticoagulant bivalirudin following angioplasty in heart attack patients reduces net adverse clinical events by 24 percent compared to the standard treatment, and significantly reduces major bleeding that occurs after angioplasty by 40 percent.
   Similar news · Read more »
   
7. Doctors' extended duration work shifts are associated with medical errors and adverse events
   12-11-2006 · EurekAlert!
   A study from the US of doctors in their first postgraduate year (interns) has showed that working extended shifts is associated with increased reporting by the doctors of medical errors, adverse patient events and attentional failures.
   Similar news · Read more »
   
8. Adverse drug events reported to FDA appear to have increased markedly
   09-10-2007 · EurekAlert!
   The number of serious adverse drug events reported to the US Food and Drug Administration more than doubled between 1998 and 2005, as did deaths associated with adverse drug events, according to a report in the Sept. 10 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
   Similar news · Read more »
   
9. Disability from long-term rheumatoid arthritis reduced with biologic treatment
   06-12-2007 · EurekAlert!
   New data demonstrating the safety and efficacy of Enbrel (etanercept) in the treatment of rheumatoid arthritis (RA) patients over the long-term were presented today at the EULAR (European League Against Rheumatism) congress (1). Over 2,000 patients receiving this biologic treatment for up to nine years, saw improvements in disability whilst safety was also sustained over the long-term.
   Similar news · Read more »
   
10. Researchers find that childhood sarcoma increases risk of blood clots
    04-18-2007 · EurekAlert!
    Researchers at NCI have determined that children and young adults with a form of cancer called sarcoma are at increased risk of having a thromboembolic event in their veins. Thromboembolic events can be a blood clot in a vessel that can interfere with normal blood flow. Investigating the association between sarcoma and TE is important because the majority of children with sarcoma can be cured of their cancer, but the occurrence of TEs could adversely compromise this success.
    Similar news · Read more »